Gala Beykin

Ophthalmology

2452 Watson Ct
Palo Alto, CA 94303

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Reply.

Reply.

Journal: Ophthalmology science

Published: May 08, 2026

Virtual reality stimulation for neuroprotection and neuroenhancement of vision in optic neuropathy patients: a prospective clinical trial.

Virtual reality stimulation for neuroprotection and neuroenhancement of vision in optic neuropathy patients: a prospective clinical trial.

Journal: BMC ophthalmology

Published: November 06, 2025

A Phase I Randomized Trial of Topical Insulin for Glaucoma: Safety and Efficacy Outcomes.

A Phase I Randomized Trial of Topical Insulin for Glaucoma: Safety and Efficacy Outcomes.

Journal: Ophthalmology science

Published: May 27, 2025

Genome wide association study and genomic risk prediction of age related macular degeneration in Israel.

Genome wide association study and genomic risk prediction of age related macular degeneration in Israel.

Journal: Scientific reports

Published: December 22, 2023

Genome-wide association study and genomic risk prediction of age-related macular degeneration in Israel.

Genome-wide association study and genomic risk prediction of age-related macular degeneration in Israel.

Journal: medRxiv : the preprint server for health sciences

Published: September 21, 2023

Phase I NT-501 Ciliary Neurotrophic Factor Implant Trial for Primary Open-Angle Glaucoma: Safety, Neuroprotection, and Neuroenhancement.

Phase I NT-501 Ciliary Neurotrophic Factor Implant Trial for Primary Open-Angle Glaucoma: Safety, Neuroprotection, and Neuroenhancement.

Journal: Ophthalmology science

Published: January 12, 2023

Corrigendum to Phase 1b Randomized Controlled Study of Short Course Topical Recombinant Human Nerve Growth Factor (rhNGF) for Neuroenhancement in Glaucoma: Safety, Tolerability, and Efficacy Measure Outcomes. Am J Ophthalmol 2022;234:223-234.

Corrigendum to Phase 1b Randomized Controlled Study of Short Course Topical Recombinant Human Nerve Growth Factor (rhNGF) for Neuroenhancement in Glaucoma: Safety, Tolerability, and Efficacy Measure Outcomes. Am J Ophthalmol 2022;234:223-234.

Journal: American journal of ophthalmology

Published: August 17, 2022

Structural and Metabolic Imaging After Short-term Use of the Balance Goggles System in Glaucoma Patients: A Pilot Study.

Structural and Metabolic Imaging After Short-term Use of the Balance Goggles System in Glaucoma Patients: A Pilot Study.

Journal: Journal of glaucoma

Published: January 07, 2022

Analysis of the Aqueous Humor Proteome in Patients With Age-Related Macular Degeneration.

Analysis of the Aqueous Humor Proteome in Patients With Age-Related Macular Degeneration.

Journal: Investigative ophthalmology & visual science

Published: August 18, 2021

Phase 1b Randomized Controlled Study of Short Course Topical Recombinant Human Nerve Growth Factor (rhNGF) for Neuroenhancement in Glaucoma: Safety, Tolerability, and Efficacy Measure Outcomes.

Phase 1b Randomized Controlled Study of Short Course Topical Recombinant Human Nerve Growth Factor (rhNGF) for Neuroenhancement in Glaucoma: Safety, Tolerability, and Efficacy Measure Outcomes.

Journal: American journal of ophthalmology

Published: July 30, 2021

Long-term outcome of neovascular age-related macular degeneration: association between treatment outcome and major risk alleles.

Long-term outcome of neovascular age-related macular degeneration: association between treatment outcome and major risk alleles.

Journal: The British journal of ophthalmology

Published: February 08, 2021

Socioeconomic status and visual outcome in patients with neovascular age-related macular degeneration.

Socioeconomic status and visual outcome in patients with neovascular age-related macular degeneration.

Journal: European journal of ophthalmology

Published: May 05, 2020

Showing 1-12 of 19

Last Updated: 09/26/2026